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We described a case of neurosarcoidosis with necrotizing sarcoid granulomatosis in a 22-year-old man. 
Contrast-enhanced brain computed tomography scan and magnetic resonance imaging showed 
intracerebral multiple nodular lesions.  Noncaseating and partial necrotizing granulomas were detected 
in the specimen resected by neurosurgery.  In addition, immunohistochemical examination revealed the 
expression of angiotensin converting enzyme in necrotizing granuloma.  Thus, these finding were 
consistent with neurosarcoidosis.  Clinical and pathological presentation, immunological feature and 
treatment modalities of neurosarcoidosis are discussed. 
 
Introduction 
Sarcoidosis is a systemic granulomatous disease of unknown etiology.  The manifestation of 
sarcoidosis in the nervous system have been recognized as neurosarcoidosis.  Especially, the 
involvement of the central nervous system (CNS) develops in about 5% of patients with systemic 
sarcoidosis [1,2].  However, because of its non-specific clinical presentation and neuroradiological 
findings, CNS lesion in neurosarcoidosis remains a very difficult diagnosis, particularly patients without 
systemic signs of the disease [3,4].  In this report, we present a sarcoidosis with epileptic seizure as the 
first symptom and intracerebral necrotic granulomas.  
 
Case Report 
  A 18-year-old Japanese man, who had been in good health, presented with generalized convulsion in 
2004.  He was taken by ambulance and admitted to a hospital nearby.  There was no significant finding 
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in brain by plain computed tomography (CT) scan.  He was diagnosed as epilepsy and was began to be 
treated with antiepileptic drug (carbamazepin 200mg/day).  No epileptic attacks occurred after the 
treatment.  In 2005, he noticed photophobia and was diagnosed as uveitis.  At the time, chest 
radiograph and CT scan showed mediastinal lymphadenopathy.  The level of serum angiotensin 
converting enzyme (ACE) were elevated at 28.5 IU/l (normal range, 8.3-21.4 IU/l).  Considered together, 
he was clinically diagnosed as sarcoidosis.  Brain CT with no enhancement was performed, however, the 
obvious abnormality was not detected.  After that, he was treated with eye drops of the steroid for 
sarcoidosis.  In 2008, he suffered from nonpulsating headache.  Contrast-enhanced CT scan and 
magnetic resonance imaging (MRI) showed multiple nodular lesions in frontal and temporal lobes, and he 
was admitted to our hospital for further examination.  
  On admission, his height was 165.5cm and his weight was 55.4kg.  His blood pressure and pulse rate 
were 116/56 mmHg and 80/min.  Examination of skin, conjunctiva, neck, thyroid gland, chest, abdomen 
and extremities revealed no abnormal signs.  On neurological examination, cranial nerves were intact.  
Muscle strength and deep tendon reflexes were normal and no pathological reflexes were observed.  
  Laboratory findings on admission are shown in Table 1.  Complete blood counts, and lactate 
dehydrogenase, calcium, and phosphorous were within normal range.  The levels of serum ACE were 
elevated at 28.7 IU/l.  Chest radiograph and CT scan revealed mediastinal lymphoadenopathy, but no 
pulmonary infiltrates (Fig.1).  Contrast-enhanced brain CT scan showed multiple nodular lesions, which 
enhanced homogeneously with contrast medium, in the right occipital, frontal, temporal, and left parietal 
lobe (Fig.2 a,b).  Gadolinium enhanced MRI showed lesions more clearly (Fig.2 c,d).  Lesions 
appeared isointense on T2-wigheted images.  They enhanced homogeneously with intravenous 
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administration of contrast medium.  To obtain the definite diagnosis, the lesion in the left parietal lobe 
was removed.  Histological examination revealed noncaseating and partial necrotizing granulomas 
(Fig.3).  In addition, ACE expression and the infiltration of CD68 positive macrophage were 
co-localized in the noncaseating granuloma and marginal area of necrotic granuloma (Fig.4).  
Mycobacterial and fungal organism were not identified on Ziehl-Neelsen and Grocott-Gomori 
methenamine silver-stained sections.  Cultures of granulomatous tissue were negative for acid-fast 
bacilli, bacteria, and fungi.  Collectively, he was diagnosed as neurosarcoidosis, and additional systemic 
investigations were performed.  Electrocardiography, echocardiography and pulmonary function tests 
showed no significant findings.  Whole-body gallium-67 scintigram showed increased uptake in the 
bilateral hilar and mediastinal regions, but no other accumulation was recognized.  Echo-guided liver 
biopsy revealed noncaseating granulomas which was relevant to sarcoidosis.  Furthermore, granulomas 
from liver biopsy were co-stained by ACE and CD68 (Fig 5).   Skin test for tuberculosis and other 
studies for infections including fungal, viral and bacterial pathogens were negative.  
  For the treatment of sarcoidosis with brain lesion, methyl-predonisolone pulse therapy was started at 
the rate of 10 mg/kg/day for consecutive 3 days; following by the oral administration of predonisolone 
(20 mg/day) according to dosages described in the review and case reports. [3,5,6].  At 6 months after 
the initiation of glucocorticoid therapy, his symptom disappeared and serum ACE level returned to normal 
(11.5 IU/l).  Contrast-enhanced CT revealed an obvious decrease of the size of intracerebral lesions (Fig 




Here, we presented a case of sarcoidosis with multiple intracranial lesions which demonstrate the 
presence of noncaseating and partial necrotizing granulomas.  This case has a history of generalized 
convulsion, photophobia diagnosed as uveitis, bilateral hilar and mediastinal lymphadenopathy and serum 
ACE elevation before developing headache. In addition, sarcoid granuloma was shown in not only brain 
but also liver biopsy.  From there findings, this case might not be isolated neurosarcoidosis.  
Sarcoidosis is an idiopathic systemic disorder that affects almost all organs in the body, including the 
CNS.  Neurological manifestations of sarcoidosis are observed in approximately 5% of patients [1,2]. In 
today, MRI has displaced contrast enhanced CT as the most useful test for detecting basal sarcoid 
meningeal desease [7].  In addition, correlation of MRI findings and clinical manifestations was reported 
[8,9].  The frequency of headache may be increasing in patients with leptomeningeal disease as in our 
case [9].   However, nonenhancing white matter, dural, and spinal lesions were the least likely to 
correlate with symptoms.  Cranial nerve enhancement and spinal lesions are more likely to resolve with 
immunosuppressive therapy than others such as dural and parenchymal lesions [9].  Enhancing 
T2-hypointense lesions may be associated with a suboptimal response to immunosuppressive therapy, but 
our case had good response to therapy. Further studies remain to be investigated to elucidate correlation 
of MRI findings and clinical manifestation in neurosarcoidosis. [9] 
Histopathology of neurosarcoidosis usually reveals the presence of noncaseating granulomas, giant 
multinucleated (epithelioid) cells and macrophages surrounded by an inflammatory reaction composed of 
lymphocytes, plasma cells, and mast cells [10].  Uncommon cases characterized by necrotizing 
granulomas such as our case have also been described [11,12].  Necrotizing sarcoid granulomatosis 
(NSG) was first described in 1973 in pulmonary sarcoidosis [13], and has been found in a variety of 
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extrapulmonary sites such as skin, kidney, and intraorbital contents.  The characteristic histological 
findings have been reported to be the coagulative central necrosis along with noncaseating granulomas 
accompanied by a moderate to intense inflammatory reaction involving lymphocytes, plasma cells, and 
macrophages [14].  The pathogenesis of NSG has been reported to be a hypersensitive reaction due to 
the vascular involvement and granulomatous inflammation [15].  Further studies will be required to 
make clear the precise mechanism of NSG. in future. 
Differential diagnosis of NSG includes chronic infections with granuloma formation (e.g.; tuberculosis, 
histoplasmosis, aspergillosis, and cryptococcosis), foreign body granulomas, Wegener’s granulomatosis, 
and idiopathic pachymeningitis with granuloma formation.  Previously, NSG in kidney have been 
reported to show the expression of ACE in granuloma [6].  In our case, similarly, ACE expression and 
macrophage infiltration were co-localized in the marginal area of necrotic granuloma.  In contrast, 
weakly stain of ACE was observed at the center of granulomas.  These findings suggested that 
inflammatory cells in sarcoid granuloma might be metabolically active in the synthesis of ACE.  
Furthermore,  immunohistochemical detection of ACE might be useful for the diagnosis of sarcoidosis, 
which help the differential diagnosis. 
Thus far, there exist no controlled studies addressing the treatment of neurosarcoidosis, including 
extra-axial nerurosarcoid granulomas.  Corticosteroids are the therapy of choice as they have been 
reported to improve neurological symptoms and reduce intracranial sarcoid spread confirmed by MRI 
[16,17,18].  In our case, corticosteroids therapy was effective and revealed an obvious decrease of the 
lesion size.  However, response to steroids has been reported to be variable.  Some cases improve 
rapidly while others do not respond at all.  Failure of response to steroid and clinical deterioration during 
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late reduction after long term administration of oral corticoids warrant additional immunosuppressive 
agent, such as azathioprine, methotrexate, cyclophosphamide, cyclosporine and mycophenolate mofetil 
[5,19,20].  In cases resistant to immunosuppressive treatment, the TNF-α antagonists,  pentoxifylline 
and thalidomide are reported to be effective and safe treatment with good steroid sparing effects 
[21,22,23].  TNF-α is thought to play a role as mediator of inflammation and cellular immune response 
among numerous cytokines involved. Infliximab (a monoclonal antibody against TNF-α) in particular has 
a growing body of literature supporting its effectiveness.  Further studies remain to be examined for 
management of this disease and avoidance of severe adverse effects. In summary, a case of 
neurosarcoidosis with NSG was described.  It may be suggested that immunohistochemical detection of 
ACE in the lesion is useful tool for the diagnosis of neurosarcoidosis with NSG. 
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Figure 1.  
 
Chest X ray on the day of admission (a). Bilateral hilar lymphadenopathy is observed.  











Figure 2.  
 
Plane CT (a) and enhanced CT (b) of the brain. Nodular lesion in right frontal lobe is observed. Extensive 
perifocal edema is present.   
Contrast-Enhanced T1-weighted MRI showed hyperintense lesion in right frontal lobe (c).  




Figure 3.  
 
Removed specimen of brain revealed noncaseating granulomas (a) as well as partial necrotizing 
granulomas (b). (hematoxylin and eosin; original magnification, a;×200, b; ×100）. 
N:necrosis 
 
Figure 4.  
 
Localization of ACE（a）and CD68（b）: ACE and CD68（macrophage）are co-localized in the marginal 





Localization of ACE（a）and CD68（b）: ACE and CD68（macrophage）are co-localized in noncaseating 
granuloma obtained from liver. （a;×400, b; ×400） 
 
Figure 6.  
 
Enhanced CT of the head; Before therapy（a）and at the six month after started oral steroid therapy（b）. 
Nodular lesion in right frontal lobe is observed decreasing the size of lesions. 
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